ReviewThe Lancet. Infectious diseases2018
Ebola virus disease: an update on post-exposure prophylaxis.
Review in The Lancet. Infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Open-Label, Expanded Access Protocol of a Human Monoclonal Antibody, Ansuvimab (mAb114), Administered As a Therapeutic to Ebola-Infected Patients or As a High-Risk Ebola Post-Exposure Prophylaxis
Evaluation of the Efficacy of a Post-exposure Prophylaxis (PEP) Strategy in Contacts at High Risk of Developing Ebola Virus Disease (EVD)
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Mapping the research landscape of antibody therapy for Ebola virus disease: a bibliometric analysis.Frontiers in immunology · 2026Pooled it
- Overcrowded Ebola treatment centers are fueling transmission in the Democratic Republic of the Congo.Nature medicine · 2026Article
- Post-exposure prophylaxis with a monoclonal antibody cocktail after Bundibugyo ebolavirus exposure in adults and children.Nature medicine · 2026Article
- From LNPs to hybrid nanocarriers: development, challenges and redesign of non-viral gene delivery.Journal of nanobiotechnology · 2026Review
- [Post-exposure prophylaxis against Ebola virus: arguments for expanding the role of monoclonal antibodies in a context of limited access].Medecine tropicale et sante internationale · 2026Review
- Poxviruses as Agents of Biological Warfare: The Importance of Ensuring Ethical Standards for Research with Viruses.Advances in experimental medicine and biology · 2024Review
- Limited Benefit of Postexposure Prophylaxis With VSV-EBOV in Ebola Virus-Infected Rhesus Macaques.The Journal of infectious diseases · 2023Article
- Postexposure-vaccine-prophylaxis against COVID-19.Journal of medical virology · 2023Article
- The Emergence of Travel-related Infections in Critical Care Units.Journal of translational internal medicine · 2022Article
- Ligand-based design of peptide entry inhibitors targeting the endosomal receptor binding site of filoviruses.Antiviral research · 2022Article
- Treatment with Ad5-Porcine Interferon-α Attenuates Ebolavirus Disease in Pigs.Pathogens (Basel, Switzerland) · 2022Article
- Ebola virus disease nosocomial infections in the Democratic Republic of the Congo: a descriptive study of cases during the 2018-2020 outbreak.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Article
- The Methanolic Extract ofViruses · 2021Article
- Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- COVID-19 Pandemic: A Case for Phytomedicines.Natural product communications · 2020Article
- Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof).Mayo Clinic proceedings · 2020Review
- Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials.CPT: pharmacometrics & systems pharmacology · 2020Review
- Postexposure Effects of Vaccines on Infectious Diseases.Epidemiologic reviews · 2019Review
- Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens.Human vaccines & immunotherapeutics · 2019Review
- Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies.Nature communications · 2018Article
Corrections and comments
- Commented on by
Authors and funding
13 authors at 11 institutions in 3 countries.
Funding
Abstract
The massive outbreak of Ebola virus disease in west Africa between 2013 and 2016 resulted in intense efforts to evaluate the efficacy of several specific countermeasures developed through years of preclinical work, including the first clinical trials for therapeutics and vaccines. In this Review, we discuss how the experience and data generated from that outbreak have helped to advance the understanding of the use of these countermeasures for post-exposure prophylaxis against Ebola virus infection. In future outbreaks, post-exposure prophylaxis could play an important part in reducing community transmission of Ebola virus by providing more immediate protection than does immunisation as well as providing additional protection for health-care workers who are inadvertently exposed over the course of their work. We propose provisional guidance for use of post-exposure prophylaxis in Ebola virus disease and identify the priorities for future preparedness and further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.